MétaCan
Menu
Back to cohort
Record W3138942180 · doi:10.1101/2021.03.11.21252971

Genetically-proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers

2021· preprint· en· W3138942180 on OpenAlexafffund
James Yarmolinsky, Virginia Díez‐Obrero, Tom G. Richardson, Marie Pigeyre, Jennifer Sjaarda, Guillaume Paré, Venexia Walker, Emma E. Vincent, Vanessa Y. Tan, Mireia Obón‐Santacana, Demetrius Albanes, Jochen Hampe, Andrea Gsur, Heather Hampel, Ellen Kampman, Rish K. Pai, Mark A. Jenkins, Steven Gallinger, Graham Casey, Wei Zheng, Christopher I. Amos, George Davey Smith, Richard M. Martin, Vı́ctor Moreno

Bibliographic record

VenuemedRxiv · 2021
Typepreprint
Languageen
FieldMedicine
TopicHormonal Regulation and Hypertension
Canadian institutionsUniversity Health NetworkThrombosis and Atherosclerosis Research InstituteUniversity of TorontoMcMaster UniversityPopulation Health Research Institute
FundersDivision of Cancer Epidemiology and Genetics, National Cancer InstituteNational Heart, Lung, and Blood InstituteInstituto de Salud Carlos IIIKnut och Alice Wallenbergs StiftelseWorld Cancer Research FundProstate Cancer FoundationMedical Research CouncilCenters for Disease Control and PreventionBiobanco VascoXunta de GaliciaMedizinische Universität GrazNational Human Genome Research InstituteCancer Council VictoriaDeutsche KrebshilfeProstate Cancer Foundation of AustraliaVetenskapsrådetUniversity of PittsburghStockholms Läns LandstingGeneralitat de CatalunyaCanadian Institutes of Health ResearchCancerfondenNational Cancer InstituteFundación Científica Asociación Española Contra el CáncerNational Institutes of HealthKarl-Franzens-Universität GrazRosetrees TrustRoyal Marsden NHS Foundation TrustCentres de Recerca de CatalunyaUmeå UniversitetEuropean CommissionHarvard T.H. Chan School of Public HealthDivision of Cancer Prevention, National Cancer InstituteAgència de Gestió d'Ajuts Universitaris i de RecercaNational Institute for Health and Care ResearchWorld Health OrganizationWageningen University and ResearchCancer Research UKGénome QuébecSwedish Cancer FoundationMcGill UniversityBreast Cancer Research FoundationPetrus och Augusta Hedlunds StiftelseJohns Hopkins UniversityCentre International de Recherche sur le CancerPelotoniaBrigham and Women's HospitalCanadian Cancer Society Research InstitutePancreatic Cancer UKOvarian Cancer Research FundU.S. Department of Health and Human ServicesNational Cancer Research InstituteOntario Ministry of Research and InnovationNational Health and Medical Research CouncilCancer Research Institute
KeywordsMendelian randomizationMedicineInternal medicineColorectal cancerGenome-wide association studyOncologySingle-nucleotide polymorphismBlood pressureOdds ratioProstate cancerCancerGenotypeBiologyGeneticsGene

Abstract

fetched live from OpenAlex

Abstract Background Epidemiological studies have reported conflicting findings on the potential adverse effects of long-term antihypertensive medication use on cancer risk. Naturally occurring variation in genes encoding antihypertensive drug targets can be used as proxies for these targets to examine the effect of their long-term therapeutic inhibition on disease outcomes. Methods Single-nucleotide polymorphisms (SNPs) in ACE , ADRB1 , and SLC12A3 associated ( P < 5.0 x 10 -8 ) with systolic blood pressure in genome-wide association studies (GWAS) were used to proxy inhibition of angiotensin-converting enzyme (ACE), β-1 adrenergic receptor (ADRB1), and sodium-chloride symporter (NCC), respectively. Summary genetic association estimates for these SNPs were obtained from GWAS consortia for the following cancers: breast (122,977 cases, 105,974 controls), colorectal (58,221 cases, 67,694 controls), lung (29,266 cases, 56,450 controls), and prostate (79,148 cases, 61,106 controls). Replication analyses were performed in the FinnGen consortium (1,573 colorectal cancer cases, 120,006 controls). Inverse-variance weighted random- effects models were used to examine associations between genetically-proxied inhibition of these drug targets and risk of cancer. Multivariable Mendelian randomization and colocalisation analyses were employed to examine robustness of findings to violations of Mendelian randomization assumptions. Results Genetically-proxied ACE inhibition equivalent to a 1 mmHg reduction in systolic blood pressure was associated with increased odds of colorectal cancer (OR 1.13, 95% CI 1.06-1.22; P = 3.6 x 10 -4 ). This finding was replicated in the FinnGen consortium (OR 1.40, 95% CI 1.02-1.92; P = 0.035). There was little evidence of association of genetically-proxied ACE inhibition with risk of breast cancer (OR 0.98, 95% CI 0.94-1.02, P = 0.35), lung cancer (OR 1.01, 95% CI 0.92-1.10; P = 0.93), or prostate cancer (OR 1.06, 95% CI 0.99-1.13; P = 0.08). Genetically-proxied inhibition of ADRB1 and NCC were not associated with risk of these cancers. Conclusion Genetically-proxied long-term ACE inhibition was associated with an increased risk of colorectal cancer, warranting comprehensive evaluation of the safety profiles of ACE inhibitors in clinical trials with adequate follow-up. There was little evidence to support associations across other drug target-cancer risk analyses, consistent with findings from short-term randomised controlled trials for these medications.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.510
Threshold uncertainty score0.650

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.022
GPT teacher head0.269
Teacher spread0.247 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2021
Admission routes2
Has abstractyes

Explore more

Same venuemedRxivSame topicHormonal Regulation and HypertensionFrench-language works237,207